Wednesday, March 4, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Oracle’s Earnings Preview: A High-Stakes Balancing Act

Jackson Burston by Jackson Burston
March 3, 2026
in AI & Quantum Computing, Analysis, Earnings, Tech & Software
0
Oracle Stock
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

As Oracle prepares to release its quarterly results on Monday, March 9, investor focus intensifies on whether its massive investments in cloud and AI infrastructure will translate into sustained profit growth. The upcoming report arrives against a backdrop of a significant analyst upgrade, a record contract backlog, and mounting financial commitments.

A Vote of Confidence from Wall Street

In a notable show of faith, the research firm Oppenheimer upgraded its rating on Oracle shares from “Perform” to “Outperform” within the last 48 hours, setting a price target of $185. The analysts’ central thesis posits that the company has the potential to become a powerful “EPS compounder,” consistently increasing its earnings per share. Their projection suggests that Oracle’s EPS could potentially double by 2030, even after applying a conservative 25% discount to management’s own ambitious targets.

This optimistic outlook is primarily anchored in the performance of Oracle’s cloud and software divisions. These segments already accounted for 86% of total revenue in the first half of fiscal year 2026. Management continues to pursue a long-term revenue goal of $225 billion by 2030. Starting from a base of $57 billion in fiscal 2025, achieving this objective would require a compound annual growth rate of approximately 31%.

The Backlog Telling a Compelling Story

A cornerstone of the investment narrative is Oracle’s staggering contractual backlog, known as Remaining Performance Obligations (RPO). This figure has surged by 438% year-over-year to reach $523 billion. The company’s recent Q2 FY2026 results showed total revenue growing 14% to $16.1 billion, with cloud revenue jumping 34% to $8.0 billion. The standout performer was Cloud Infrastructure (IaaS), which skyrocketed 68% compared to the prior-year period.

Oracle attributes this massive pipeline to demand from high-profile clients including Nvidia, Meta, OpenAI, AMD, TikTok, and xAI. For investors, the timing of revenue recognition is key. The company anticipates realizing roughly 10% of the RPO as revenue within the next 12 months, a further 30% between months 13 and 36, and another 35% between months 37 and 60. This schedule underscores long-term visibility while spreading the financial harvest over several years.

Should investors sell immediately? Or is it worth buying Oracle?

Financing a Costly Transformation

Building out AI infrastructure demands substantial capital. Oracle plans to raise $45 to $50 billion in gross new capital during calendar year 2026 through a mix of debt and equity, aiming to preserve its investment-grade credit rating. A $25 billion bond issuance was completed in February, complemented by an equity placement program of up to $20 billion. With cash reserves standing at $19.2 billion at the end of Q2 FY2026, immediate liquidity concerns appear contained.

However, the expansion is not without its challenges and critics. On January 14, bondholders filed a class-action lawsuit in Manhattan, alleging that Oracle failed to disclose the need for significantly more debt during a previous bond offering. Furthermore, a late-February report from The Information cast doubt on the operational structure of the Stargate joint venture, claiming it was minimally staffed and did not directly control data centers. This news reportedly pressured the stock, contributing to a 6% decline at the time. Concurrently, the company’s total debt has now surpassed the $100 billion mark.

Providing context to the current sentiment, Oracle’s shares are trading at 125.22 euros, reflecting a substantial year-to-date decline of 25.02%.

The March 9 Report: Key Metrics to Watch

All eyes are on the pre-market release on Monday, March 9, for Oracle’s Q3 FY2026 earnings. Consensus estimates are calling for adjusted earnings per share of approximately $1.71 on revenue of about $16.91 billion. The critical questions for the market will be whether Oracle can maintain its current growth velocity, demonstrate control over the costs associated with its AI expansion, and provide convincing evidence within the financials that its OCI (Oracle Cloud Infrastructure) strategy is delivering as planned.

Ad

Oracle Stock: Buy or Sell?! New Oracle Analysis from March 4 delivers the answer:

The latest Oracle figures speak for themselves: Urgent action needed for Oracle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 4.

Oracle: Buy or sell? Read more here...

Tags: Oracle
Jackson Burston

Jackson Burston

Related Posts

Biodexa Pharmaceuticals Stock
Analysis

Biodexa Charts Ambitious Course with New Asset and Leadership

March 4, 2026
Microsoft Stock
Analysis

Microsoft Shares Find Relief Amidst Prolonged Downturn

March 3, 2026
Oracle Stock
Analysis

Oracle’s Government Cloud Approvals Spark Investor Interest Amid Legal Scrutiny

March 3, 2026
Next Post
Super Micro Computer Stock

Super Micro Computer Expands Telecom Footprint with AI Infrastructure Push

Marvell Technology Stock

Marvell Technology's Pivotal Week: Earnings and Strategy in Focus

Abbott Laboratories Stock

Abbott Laboratories Secures Major Acquisition Funding Amid Legal Headwinds

Recommended

Inspired Entertainment Inc Implements Strategy to Address Compliance Issue with Nasdaq

2 years ago
Viking Therapeutics Stock

Viking Therapeutics Stock Gains Momentum on Promising Clinical Data

1 month ago
Biotechnology Market Capitalization

Analysts Remain Positive on IPG Photonics Despite Slight Decrease in Price Target

2 years ago
Dental_Lab_digital

Voya Financial Announces Leadership Succession Plan for Voya Investment Management

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Oracle’s Government Cloud Approvals Spark Investor Interest Amid Legal Scrutiny

Broadcom’s Dual-Pronged Strategy: Targeting Telecom Efficiency and AI Chip Dominance

A Shift in Global Exposure: US Weighting Declines in Major World ETF

AMD’s Strategic Surge: Meta Partnership and AI Expansion Drive Growth Ambitions

IBM Faces AI Disruption in Its Legacy Software Stronghold

Eli Lilly’s Oral Obesity Drug Nears Key Milestone as Pipeline Expands

Trending

Biodexa Pharmaceuticals Stock
Analysis

Biodexa Charts Ambitious Course with New Asset and Leadership

by Jackson Burston
March 4, 2026
0

Biodexa Pharmaceuticals is laying the groundwork for a pivotal phase in its development, targeting 2026 with a...

Microsoft Stock

Microsoft Shares Find Relief Amidst Prolonged Downturn

March 3, 2026
Strategy Stock

Strategy Inc. Doubles Down on Bitcoin with Fresh $204 Million Purchase

March 3, 2026
Oracle Stock

Oracle’s Government Cloud Approvals Spark Investor Interest Amid Legal Scrutiny

March 3, 2026
Broadcom Stock

Broadcom’s Dual-Pronged Strategy: Targeting Telecom Efficiency and AI Chip Dominance

March 3, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Biodexa Charts Ambitious Course with New Asset and Leadership
  • Microsoft Shares Find Relief Amidst Prolonged Downturn
  • Strategy Inc. Doubles Down on Bitcoin with Fresh $204 Million Purchase

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com